Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Co-Diagnostics ( (CODX) ) has shared an announcement.
On September 30, 2025, Co-Diagnostics, Inc. announced its participation in the Lytham Partners Fall 2025 Investor Conference, where it will present a webcast and conduct one-on-one meetings with institutional investors. This engagement is part of the company’s efforts to strengthen its industry positioning and foster relationships with stakeholders, potentially impacting its operations and market presence.
The most recent analyst rating on (CODX) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Co-Diagnostics stock, see the CODX Stock Forecast page.
Spark’s Take on CODX Stock
According to Spark, TipRanks’ AI Analyst, CODX is a Neutral.
Co-Diagnostics is currently facing significant financial difficulties, with declining revenues and profitability being the most impactful factors. While there is some bullish momentum in the technical indicators, the overall financial health and valuation concerns weigh heavily on the stock’s attractiveness.
To see Spark’s full report on CODX stock, click here.
More about Co-Diagnostics
Co-Diagnostics, Inc., based in Utah, is a molecular diagnostics company specializing in the development, manufacturing, and marketing of advanced diagnostic technologies. Their products are designed to detect and analyze nucleic acid molecules, with applications extending beyond infectious diseases to include genetic marker identification.
Average Trading Volume: 6,667,458
Technical Sentiment Signal: Sell
Current Market Cap: $17.82M
For a thorough assessment of CODX stock, go to TipRanks’ Stock Analysis page.